Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma...

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Cellular phenotypes are determined by integrated signals from multiple pathways.
• Glioblastoma multiforme (GBM) is an aggressive brain tumor with complex signaling networks.

Purpose of the Study:

• To investigate the multivariate signaling regulatory functions of protein tyrosine phosphatase SHP2 (PTPN11) in GBM.
• To elucidate how SHP2 integrates ERK1/2 and STAT3 signaling to affect GBM cell phenotypes.

Main Methods:

• Investigated SHP2's role in regulating ERK1/2 and STAT3 pathways in GBM cells.
• Assessed the impact of SHP2 on GBM cell proliferation and resistance to EGFR and c-MET co-inhibition.
• Examined SHP2 function in GBM cells expressing EGFR variant III (EGFRvIII).

Main Results:

• SHP2 simultaneously drives ERK1/2 (proliferation) and antagonizes STAT3 (cell death) signaling.
• SHP2-driven ERK1/2 activity is dominant for proliferation, while SHP2 antagonism of STAT3 promotes cell death.
• SHP2's regulatory functions are diminished in EGFRvIII-expressing GBM cells.
• In EGFRvIII+ cells, SHP2 antagonizes EGFRvIII and c-MET phosphorylation and drives HIF-1α/HIF-2α expression.

Conclusions:

• SHP2 plays a critical, dual role in GBM cell proliferation and death through differential regulation of ERK1/2 and STAT3 pathways.
• EGFRvIII expression modifies SHP2's signaling functions in GBM, impacting therapeutic resistance and potentially driving tumor adaptation.
• Understanding SHP2's complex roles in GBM, especially in the context of EGFRvIII, is crucial for developing targeted therapies.